rais price strong
strong convers patient trikafta combin ex-u
inventori build ensur suppli pandem drive strong
quarterli result reiter market outperform rate rais risk-
adjust dcf-deriv price target
impress execut trikafta launch continu despit
pandem sale came nearli twice high expect
figur drive total cf franchis revenu
increas guidanc formerli due
beat though caution drift toward normal complianc
channel level combin potenti access issu amidst
pandem temper continu high growth strong quarter
pipelin activ remain larg track addit data
compani gene edit program hemoglobinopathi
anticip year poc studi defici
set resum near futur
financi detail figur vertex report significantli better
expect non-gaap cf revenu beat driven
trikafta achiev sale vs consensu estim
jmpe result increas total cf revenu
guidanc though acknowledg
actual figur may lower end rang patient complianc
persist natur declin launch expect trikafta
roll-out primari investor focu throughout compani seek
pursu addit sourc growth snda submiss
children age year plan potenti eu approv
year older could occur expect materi
revenu start
pipelin pleas pandem limit
impact view compani non-cf pipelin although compani
temporarili paus screen enrol phase studi
defici manag plan resum trial soon data
expect expect updat timelin
near futur meanwhil addit phase data compani gene
edit program sever hemoglobinopathi still track
readout later year phase studi fsg initi
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
earlier month also activ busi develop
front strengthen gene therapi platform week collabor
affinia privat nc toward dmd cf
take continu recommend share growth cf
franchis despit challeng pandem showcas
compani domin space essenti natur medicin
slightli lower discount rate rais
cf revenu estim result new
figur financi result estim
cambridg massachusetts-bas vertex pharmaceut biotechnolog compani busi discov develop
commerci small molecul drug seriou diseas vertex princip focu develop commerci new
treatment cystic fibrosi cf compani market kalydeco orkambi symdeko trikafta treat cf
clinic develop risk drug develop riski capital-intens endeavor major drug enter clinic develop
fail reach market
competit risk drug market develop condit vertex develop program address
lack differenti clinic data vertex drug and/or approv competit drug may advers impact sale potenti
regulatori risk vertex like drug develop compani reliant upon fda pace evalu new drug agenc
willing approv new drug
fund risk relianc capit market pose risk term investor appetit biotech stock degre dilut depend
upon time deal
sector risk valuat biotechnolog stock subject investor assess prospect underli compani
investor risk toler confid prospect biotechnolog stock group therefor vertex stock price may fall even
compani meet exce investor expect
research analyst prepar report does/do herebi certifi view present report accord my/our
person view secur issuer discuss report mandat sec regul ac part my/our compens
directli indirectli relat specif view recommend express herein certif made
oblig set forth sec regul ac person entiti may use purpos certif made
base my/our analysi date report public i/w assum oblig updat certif reflect fact
circumst event may subsequ come my/our attent sign liisa bayko jonathan wolleben neil panchal
jmp secur current make market secur incorpor
jmp secur expect receiv intend seek compens invest bank servic vertex pharmaceut
incorpor next month
disclaim detail pleas click link
applic disclosur compani mention report pleas refer jmp fact disclosur page report link
market outperform mo jmp secur expect stock price outperform relev market indic next month
market perform mp jmp secur expect stock price perform line relev market indic next month
market under-perform mu jmp secur expect stock price under-perform relev market indic next month
jmp secur research rate invest bank servic april
co
servic
stock price chart rate price chang
note first annot denot initi coverag year whichev shorter target price list target price n/a
accord finra rule chart reflect price rang chang rate price target end
recent calendar quarter action reflect note annot stock price chart jmp secur
jmp secur llc firm compens research analyst like firm employe base firm profit includ
revenu firm institut sale trade invest bank depart well qualiti servic activ
perform intend benefit firm institut client data prepar jmp secur llc inform
purpos base inform avail public sourc believ reliabl guarante
accuraci complet opinion project express herein reflect judgment date subject chang
without notic data neither intend consid offer sell solicit basi contract
purchas secur financi product jmp secur llc affili jmp group llc harvest capit strategi llc
respect partner director offic associ may long short posit may act market maker may
purchas sell posit secur mention herein jmp secur llc affili may perform perform seek
perform invest bank advisori servic may act manag co-manag public offer secur
compani mention herein reader assum jmp secur llc solicit busi compani cover
report member sale trade depart provid oral and/or written market opinion trade strategi client
reflect person opinion stock subject firm research report research analyst discuss trade
strategi client sometim reflect short-term expect price secur subject research report
trade strategi distinct analyst fundament rate stock base upon analyst view compar
stock coverag relev time period copyright right reserv jmp secur llc jmp secur
llc member finra sipc
director research
director equiti
director sale trade
